Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hypercholesterolemic model.

Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hypercholesterolemic model.

PMID: 

Benef Microbes. 2019 May 28 ;10(5):555-567. Epub 2019 May 15. PMID: 31090460

Abstract Title: 

changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model.

Abstract: 

Hypercholesterolemia is a main risk factor of cardiovascular disease. Probiotics are a safe approach to reduce elevated cholesterol without any deleterious effect to human health.CNCM I-745 probiotic properties are well documented in a context of intestinal dysbiosis. Recentand preclinical studies have suggested its potential effects on dyslipidemia. This is the first controlled study investigating the effects ofCNCM I-745 on lipidemic profile and gut microbiota in a hamster hypercholesterolemic model. Daily administration (3 g/kg) offor 21 or 39 days in hamsters fed a 0.3% cholesterol-diet significantly reduced total plasma cholesterol (

read more

15
Like
Save

Comments

Write a comment

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.